Craif raised $33 million in a Series D to accelerate a urine-based pancreatic cancer test toward U.S. clinical trial execution. The funding is aimed at scaling laboratory capacity in San Diego, pursuing CLIA certification, and preparing a clinical utility story for entry into the U.S. market, beginning with high-risk participants identified by pancreatic anatomical abnormalities. The company’s platform uses microRNA analysis from urine exosomes and includes an AI-driven device component for pancreatic risk scoring. In parallel, Craif said it plans to submit for Japanese regulatory evaluation for a related AI-enabled device via PMDA. For diagnostics developers, the financing indicates investor appetite for non-invasive cancer detection tools that can pair lab methods with algorithmic risk scoring—though the near-term benchmark remains clinical utility readouts and reimbursement pathways.